Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 4,992
- 试验地点
- 1
- 主要终点
- Medical information
研究概览
简要总结
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
详细描述
AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.
- •No Exclusion Criteria.
排除标准
- 未提供
结局指标
主要结局
Medical information
时间窗: At baseline visit
History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors
Drug exposure
时间窗: Past
Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
次要结局
- Other medical events of interest(During follow-up (up to 12 months))